| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Articles |
1
The Futhan/EDTA tubes are produced by Terumo Europe and can be purchased from PerSeptive Biosystems, 500 Old Connecticut Path, Framingham, MA 01701. At present, the Futhan/EDTA tubes are approved only for research use in the United States.
a Address correspondence to this author at: Department of Immunology/IMM-18, The Scripps Research Institute, 10550 N. Torrey Pines Rd., La Jolla, CA 92037. Fax 619-784-8307; e-mail hugli{at}scripps.edu
Background: Ongoing in vitro complement (C) activation in citrate or EDTA plasma has prevented an accurate analysis of C-activation products generated in vivo. The aim of this study was to characterize handling and storage conditions required to prevent in vitro C activation in blood and plasma samples collected with Futhan/EDTA.
Methods: BiotrakTM RIAs were used to quantitatively measure C3a and C4a in blood and/or plasma samples from healthy individuals (controls) and from liver transplant patients. Blood samples were routinely drawn into either EDTA (1 g/L) tubes or into tubes containing both EDTA (1 g/L) and Futhan (0.1 g/L) and immediately centrifuged at 2000g for 15 min at 4 °C.
Results: In controls, C4a, but not C3a, in fresh samples (time 0) was higher in EDTA plasma than in Futhan/EDTA plasma (n = 20; P = 0.002). Futhan/EDTA prevented C3a and C4a generation in blood and plasma samples held at room temperature (22–23 °C) for 1 h and in plasma held for 24 h at 4 °C or -70 °C. The mean C3a concentration (1.76 mg/L; n = 19) at time 0 in EDTA plasma samples from liver transplant patients was significantly higher than for controls (0.34 mg/L; n = 11). In these patients, the mean C3a in EDTA samples increased to 13.8 mg/L after 60 min at room temperature, but there was no change in the C3a concentration of an EDTA plasma from a control. In the patients, C3a concentrations were lower in Futhan/EDTA plasma than in EDTA at time 0 and after 60 min at room temperature (1.40 and 2.02 mg/L, respectively). The mean patient C4a was 4.02 mg/L in EDTA plasma at time 0 vs 0.24 mg/L for controls; it increased to 16.9 mg/L after 60 min at room temperature compared with 0.76 mg/L for controls. The mean patient C4a was 0.83 mg/L in Futhan/EDTA plasma at time 0 vs 0.1 mg/L for controls. Neither patient nor control C4a concentrations increased vs time in Futhan/EDTA.
Conclusion: The combination of Futhan (0.1 g/L) and EDTA (1 g/L) eliminates in vitro C activation.© 1999 American Association for Clinical Chemistry
The following articles in journals at HighWire Press have cited this article:
|
|
 |
|
  L. R. La Bonte, B. Dokken, G. Davis-Gorman, G. L. Stahl, and P. F. McDonagh The mannose-binding lectin pathway is a significant contributor to reperfusion injury in the type 2 diabetic heart Diabetes and Vascular Disease Research, July 1, 2009; 6(3): 172 - 180. [Abstract] [PDF]
|
|
|
|
 |
|
 J. Tian, Z. Xu, J. S. Smith, S. E. Hofherr, M. A. Barry, and A. P. Byrnes Adenovirus Activates Complement by Distinctly Different Mechanisms In Vitro and In Vivo: Indirect Complement Activation by Virions In Vivo J. Virol., June 1, 2009; 83(11): 5648 - 5658. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K Oku, T Atsumi, M Bohgaki, O Amengual, H Kataoka, T Horita, S Yasuda, and T Koike Complement activation in patients with primary antiphospholipid syndrome Ann Rheum Dis, June 1, 2009; 68(6): 1030 - 1035. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. E. Burns, K. M. Edwards, C. Ring, M. Drayson, and D. Carroll Complement Cascade Activation After an Acute Psychological Stress Task Psychosom Med, May 1, 2008; 70(4): 387 - 396. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. R. La Bonte, G. Davis-Gorman, G. L. Stahl, and P. F. McDonagh Complement inhibition reduces injury in the type 2 diabetic heart following ischemia and reperfusion Am J Physiol Heart Circ Physiol, March 1, 2008; 294(3): H1282 - H1290. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Honczarenko, M. Z. Ratajczak, A. Nicholson-Weller, and L. E. Silberstein Complement C3a Enhances CXCL12 (SDF-1)-Mediated Chemotaxis of Bone Marrow Hematopoietic Cells Independently of C3a Receptor J. Immunol., September 15, 2005; 175(6): 3698 - 3706. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. E. Banks, A. J. Stanley, D. A. Cairns, J. H. Barrett, P. Clarke, D. Thompson, and P. J. Selby Influences of Blood Sample Processing on Low-Molecular-Weight Proteome Identified by Surface-Enhanced Laser Desorption/Ionization Mass Spectrometry Clin. Chem., September 1, 2005; 51(9): 1637 - 1649. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Kirschfink and T. E. Mollnes Modern Complement Analysis Clin. Vaccine Immunol., November 1, 2003; 10(6): 982 - 989. [Full Text] [PDF]
|
|
|
|
|
|
H. Tani, C. K. Limn, C. C. Yap, M. Onishi, M. Nozaki, Y. Nishimune, N. Okahashi, Y. Kitagawa, R. Watanabe, R. Mochizuki, et al. In Vitro and In Vivo Gene Delivery by Recombinant Baculoviruses J. Virol., September 15, 2003; 77(18): 9799 - 9808. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Furuya, H. Takeda, S. Azhar, R. M. McCarron, Y. Chen, C. A. Ruetzler, K. M. Wolcott, T. J. DeGraba, R. Rothlein, T. E. Hugli, et al. Examination of Several Potential Mechanisms for the Negative Outcome in a Clinical Stroke Trial of Enlimomab, a Murine Anti-Human Intercellular Adhesion Molecule-1 Antibody: A Bedside-to-Bench Study Stroke, November 1, 2001; 32(11): 2665 - 2674. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
